In Vitro: BMS794833 inhibits Met receptor activated gastric carcinoma cell line, GTL-16, with an IC50 of 39 nM.
In Vivo: BMS-794833 is active by greater than 50% tumor growth inhibition for at least one tumor doubling time in the GTL-16 gastric carcinoma model. No toxicity is observed at any of the dose levels when administered once daily for a duration of 14 days.